Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors.

PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.


Clinical Trial Description

OBJECTIVES:

Primary

- To determine the objective response rate in patients with neuroendocrine tumors treated with capecitabine and streptozocin with or without cisplatin.

Secondary

- To determine the overall response rate, including both objective and biochemical responses, to these regimens.

- To determine the functional response to these regimens.

- To determine the toxicity of these regimens.

- To identify the optimal drug doses in each regimen to be recommended for a subsequent phase III trial.

- To determine the progression-free and overall survival of patients receiving these regimens.

- To determine the quality of life of these patients.

- To determine molecular markers predictive of response to chemotherapy.

OUTLINE: This is a multicenter study. Patients are stratified according to site of origin (known vs unknown primary site), prior antitumor treatment, tumor function (functional vs nonfunctional), and study center. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive streptozocin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-21.

- Arm II: Patients receive cisplatin IV over 2 hours on day 1 and streptozocin and capecitabine as in arm I.

In both treatment arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients complete the EORTC QLQC30 questionnaire and EORTC QLQ-GI.NET21 module for quality-of-life assessment at baseline, every 9 weeks during treatment, and at 12 weeks post-treatment.

Tumor tissue is obtained at baseline and assessed for Ki67 and mitotic index. Novel tissue-specific transcription factors (e.g., CDX2) are also assessed. Blood samples are collected at baseline and 9 weeks and examined by DNA, RNA, and proteomic analysis.

After completion of study therapy, patients are followed every 12 weeks. ;


Study Design

Allocation: Randomized, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00602082
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date August 2005
Completion date December 2009

See also
  Status Clinical Trial Phase
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Completed NCT00002470 - Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Phase 2
Active, not recruiting NCT00454376 - Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Phase 4
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00427349 - AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Phase 2
Completed NCT00416767 - Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Phase 2
Completed NCT00005049 - Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Phase 2
Completed NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00019474 - Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3
Completed NCT00654160 - Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Phase 1
Completed NCT00049023 - Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Phase 1
Completed NCT00004910 - Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Phase 1/Phase 2
Completed NCT00004911 - Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Phase 1/Phase 2
Completed NCT00006368 - Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Phase 1
Active, not recruiting NCT00730483 - Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors N/A
Completed NCT00017199 - PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00003427 - Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Phase 1